ATE419242T1 - Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren - Google Patents

Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren

Info

Publication number
ATE419242T1
ATE419242T1 AT04785388T AT04785388T ATE419242T1 AT E419242 T1 ATE419242 T1 AT E419242T1 AT 04785388 T AT04785388 T AT 04785388T AT 04785388 T AT04785388 T AT 04785388T AT E419242 T1 ATE419242 T1 AT E419242T1
Authority
AT
Austria
Prior art keywords
pyrrolidinylurea
derivatives
angiogenesis inhibitors
compounds
methods
Prior art date
Application number
AT04785388T
Other languages
English (en)
Inventor
Fortuna Haviv
Michael Bradley
Daryl Sauer
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE419242T1 publication Critical patent/ATE419242T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Pyrrole Compounds (AREA)
AT04785388T 2003-10-09 2004-10-08 Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren ATE419242T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68249703A 2003-10-09 2003-10-09

Publications (1)

Publication Number Publication Date
ATE419242T1 true ATE419242T1 (de) 2009-01-15

Family

ID=34435386

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04785388T ATE419242T1 (de) 2003-10-09 2004-10-08 Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren

Country Status (6)

Country Link
EP (1) EP1680415B1 (de)
AT (1) ATE419242T1 (de)
CA (1) CA2540868A1 (de)
DE (1) DE602004018811D1 (de)
ES (1) ES2318343T3 (de)
WO (1) WO2005035524A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745427B2 (en) 2004-10-22 2010-06-29 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913999PA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds
MX394645B (es) * 2017-06-12 2025-03-21 Boehringer Ingelheim Int Compuestos heteroaromáticos como inhibidores de vanina.
DK3844161T3 (da) 2018-08-28 2022-12-12 Boehringer Ingelheim Int Heteroaromatiske forbindelser som vanininhibitorer.
WO2020114947A1 (en) 2018-12-03 2020-06-11 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as vanin inhibitors
SG11202104437XA (en) 2018-12-03 2021-05-28 Boehringer Ingelheim Int Heteroaromatic compounds as vanin inhibitors
JP7080405B2 (ja) 2018-12-03 2022-06-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング バニン阻害剤としての複素芳香族化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2276519T3 (es) * 1998-05-22 2007-06-16 Abbott Laboratories Un medicamento antiangiogenico para el tratamiento del cancer, de la artritis y de la retinopatia.
US20030216396A1 (en) * 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity

Also Published As

Publication number Publication date
EP1680415B1 (de) 2008-12-31
ES2318343T3 (es) 2009-05-01
WO2005035524A1 (en) 2005-04-21
CA2540868A1 (en) 2005-04-21
DE602004018811D1 (de) 2009-02-12
EP1680415A1 (de) 2006-07-19

Similar Documents

Publication Publication Date Title
ATE360627T1 (de) Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
ATE433447T1 (de) Pyrimiidinverbindungen
PL363168A1 (pl) Cyklopentanole, kompozycje zawierające takie związki i sposoby leczenia
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
ATE484508T1 (de) Furylverbindungen
NO20044995L (no) Heterosykliske forbindelser
TW200608977A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
NO20044526L (no) Hemisterlinderivater og anvendelser derav
DE60221425D1 (de) Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase-inhibitoren
DE60316984D1 (de) Benzoylsulfonamide als antitumor-mittel
SE0103710D0 (sv) Compounds
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ATE498600T1 (de) Inden derivate als pharmazeutika
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
EA200600100A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
DE60329326D1 (de) Tace inhibitoren
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
EA200600601A1 (ru) Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties